Ann: Australian Distribution Agreement for 9000 HeraBEAT Units, page-2

With the Teva agreement and this one they are saying 1m (minimum) a year for the next 3 years in revenue. They already have CE and TGA. This is for only 2 small locations.
Many companies on the ASX would like to have revenue at the same stage of development.

More importantly is market penetration and the word of mouth on all the pregnancy websites and blogs which are certainly not geographically confined. Once this becomes broadly available it will spread very rapidly I believe. When it is in the community the health services will need to deal with it much faster than they may otherwise like to as mums will come in with results for analysis. This will speed the uptake as a more significant medical device (which it is) and take some of the timing decisions out of the hands of (generally) slow-moving institutions.

Much to like here.